Seeger Weiss Seeking Claims Against Merck For Fosamax Injuries
Seeger Weiss LLP announces that it is investigating claims against Merck & Co. (NYSE: MRK) for Fosamax-related injuries, including reports of osteonecrosis of the jaw. Fosamax, marketed by Merck, is indicated for the treatment and prevention of osteoporosis (thinning of the bones) in men and women. Recent studies, however, suggest a link between the use of bisphosphonates, such as Fosamax, and osteonecrosis of the jaw, also known as "jaw death.'' This condition is associated with the interference of the blood supply to the bone and the consequential damage that occurs. Osteonecrosis of the jaw can be extremely painful and may lead to additional complications, such as infection, breakdown of the jawbone, and ulcerations in the lining of the mouth. It is not known if discontinuing the use of Fosamax can lower the risk of osteonecrosis of the jaw, because the bisphosphonate medications metabolize slowly and remain in the bones for many years.
If you have taken Fosamax and experienced any of the aforementioned side-effects, please contact Seeger Weiss for a free case evaluation.
